1. Home
  2. XPEV vs GKOS Comparison

XPEV vs GKOS Comparison

Compare XPEV & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XPeng Inc.

XPEV

XPeng Inc.

N/A

Current Price

$11.87

Market Cap

12.5B

ML Signal

N/A

Logo Glaukos Corporation

GKOS

Glaukos Corporation

N/A

Current Price

$182.00

Market Cap

10.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XPEV
GKOS
Founded
2015
1998
Country
China
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.5B
10.6B
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
XPEV
GKOS
Price
$11.87
$182.00
Analyst Decision
Buy
Strong Buy
Analyst Count
5
12
Target Price
$23.08
$126.92
AVG Volume (30 Days)
5.7M
818.6K
Earning Date
05-20-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$507,442,000.00
Revenue This Year
$25.76
$23.32
Revenue Next Year
$25.98
$27.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.33
52 Week Low
$11.54
$73.16
52 Week High
$28.20
$184.00

Technical Indicators

Market Signals
Indicator
XPEV
GKOS
Relative Strength Index (RSI) 36.34 80.94
Support Level $11.77 $99.75
Resistance Level $13.34 $184.00
Average True Range (ATR) 0.31 7.47
MACD -0.05 1.53
Stochastic Oscillator 14.21 95.68

Price Performance

Historical Comparison
XPEV
GKOS

About XPEV XPeng Inc.

Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold about 430,000 EVs in 2025, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: